The Franklin team are pleased to be joined by new Chief Operating Officer, Dr Paul McCubbin.
Paul has worked in the life science sector for over 20 years, starting his career with a doctorate in Cell Biology from the University of Oxford, before moving onto roles at Ernst and Young and Profiad, a spin out from Glaxo SmithKline. Paul joins the team from BTG plc, a FTSE 250 healthcare company acquired for $4.2bn by Boston Scientific in August 2019, where he held a number of roles, most recently as Head of Strategy and Business Development and as member of the executive leadership team.
With this wealth of expertise in strategic planning, business development, and finance, Paul will lead the operations team, and oversee the delivery of the vision of the Franklin alongside Director Jim Naismith and Chair Vivienne Cox.
Dr Paul McCubbin
Paul said “Healthcare companies, both pharmaceutical and devices, are becoming increasingly dependent on partnerships to access innovation. No other institute can offer what the Franklin is creating. The ability to contribute to the Institute’s vision, which resonates so strongly with trends in life science, is incredibly exciting, and I am looking forward to working with the team at Harwell and in the spokes.”